Aytu BioPharma to Be Acquired in $56 Million Cash Deal
Denver, Monday, 16 November 2026.
Alongside reporting a 6.9% quarterly revenue increase, Aytu BioPharma agreed to a $56 million buyout by Rosemont Pharmaceuticals, canceling its earnings call to finalize the acquisition.
Aytu BioPharma’s Q1 Fiscal 2027 Financial Performance
Aytu BioPharma, Inc. (NASDAQ: AYTU) reported its first quarter financial results for fiscal 2027 on November 16, 2026, highlighting a 6.9% year-over-year increase in net revenue to $14.8 million from $13.9 million in Q1 fiscal 2026 [alert! ‘Fiscal years may not align with calendar years for all companies’][1]. The company’s EXXUA product, a novel oral selective serotonin 5-HT1A receptor agonist for treating major depressive disorder (MDD) in adults, contributed $4.9 million in net revenue for the quarter, representing a 24.5% increase from Q4 fiscal 2026 [alert! ‘Quarter-over-quarter comparisons may vary based on reporting periods’][1]. EXXUA’s total prescriptions rose 32.5% sequentially to 4,400, including a monthly high of approximately 1,650 in September 2026 [1]. The company’s ADHD Portfolio and Pediatric Portfolio generated $7.7 million and $2.2 million in net revenue, respectively [1].
Financial Challenges and Strategic Shift
Despite revenue growth, Aytu BioPharma reported a net loss of $3.9 million and an Adjusted EBITDA loss of $2.6 million for Q1 fiscal 2027, compared to a net income of $2.0 million in Q1 fiscal 2026 [1]. The company’s cash and cash equivalents totaled $25.5 million as of September 30, 2026, down from $26.3 million at the end of the prior quarter [1]. These financial challenges coincide with Aytu’s strategic pivot toward a pending merger with Rosemont Pharmaceuticals Holdings, Inc., announced on November 16, 2026 [1]. The merger agreement, structured as a cash tender offer at $2.70 per share, values the transaction at approximately $56 million on a fully-diluted basis [1].
Merger Agreement and Regulatory Path Forward
The definitive merger agreement between Aytu BioPharma and Rosemont Pharmaceuticals was formalized on November 16, 2026, with Aytu confirming it would not host an earnings conference call to discuss Q1 fiscal 2027 results, focusing instead on regulatory and closing requirements for the cross-border pharmaceutical consolidation [1]. The transaction is expected to be completed by the end of calendar 2026, pending regulatory approvals and shareholder acceptance [alert! ‘Merger completion is contingent on multiple variables’][1]. Aytu’s CEO Josh Disbrow emphasized the strategic fit between Aytu’s CNS and pediatric portfolio and Rosemont’s expertise in developing specialty medicines, stating the deal delivers ‘compelling value to our shareholders’ [1].
EXXUA: A Key Growth Driver Amid Portfolio Expansion
EXXUA (gepirone) represents a significant growth driver for Aytu BioPharma, with its net revenue increasing to $4.9 million in Q1 fiscal 2027, up 24.5% from the prior quarter [1]. The product’s dosage titrations include incremental increases from 18.2 mg to a maximum of 72.6 mg once daily, with adjustments for geriatric and renally or hepatically impaired patients [1]. However, EXXUA carries several contraindications, including hypersensitivity to gepirone, baseline QTc > 450 msec, and concomitant use of strong CYP3A4 inhibitors, as well as warnings for QT prolongation, serotonin syndrome, and mania activation [1]. Clinical studies reported acute ingestions up to 454 mg (6.25 times the maximum recommended dose), resulting in symptoms such as vomiting and transient incomplete bundle branch block [1].